Pharmaceutical compositions containing LTV-17 and a β-lactamase inhibitor and their use as antibacterial agents

LTV-17 and β-lactamase inhibitors form synergistic drug combinations that overcome bacterial resistance by enhancing antibacterial activity against ESKAPE pathogens, addressing the challenge of antibiotic resistance.

JP2024544139APending Publication Date: 2024-11-28FEDORA PHARMACEUTICALS INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024527741
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-12
Filing Date
2022-11-10
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

ESKAPE pathogens have developed resistance to commonly used β-lactam antibiotics due to the production of β-lactamases, necessitating the development of new antibacterial agents with non-β-lactam structural motifs and synergistic combinations to enhance treatment efficacy.

Method used

Combining LTV-17, a lactibicin derivative without a β-lactam structural motif, with selected β-lactamase inhibitors to create synergistic drug combinations that exhibit enhanced antibacterial activity against resistant bacteria.

Benefits of technology

The combination of LTV-17 with β-lactamase inhibitors demonstrates a synergistic effect, providing greater antimicrobial activity than either component alone, effectively targeting and inhibiting a wide range of Gram-negative bacteria, including ESKAPE pathogens.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544139000001
    Figure 2024544139000001
  • Figure 2024544139000002
    Figure 2024544139000002
  • Figure 2024544139000003
    Figure 2024544139000003
Patent Text Reader

Abstract

A pharmaceutical combination of LTV-17(I), a lacticin derivative, and a β-lactamase inhibitor is provided, the combination comprising an antibacterial agent suitable for use in the treatment or prevention of a bacterial infection.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to drug compounds and their use in the treatment of microbial infections. More specifically, a drug (or pharmaceutical) combination is provided in which an antibacterial activicin derivative is combined with a certain β-lactamase inhibitor, which exhibit synergistic activity against many resistant pathogenic microorganisms. [Background technology]

[0002] While resistant bacterial isolates continue to emerge in the hospital environment, physicians are also encountering an increasing number of resistant bacteria in the community, particularly multidrug-resistant Gram(-) pathogens, including the bacteria that make up the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species). One of the most common resistance mechanisms to the commonly used β-lactam antibiotics is the production by resistant bacteria of a group of enzymes called β-lactamases. To overcome this resistance, β-lactamase inhibitors have been developed by many groups and are commonly used in clinical settings.

[0003] Another option is to develop new classes of antibiotics: given the increasing expression of bacterial β-lactamases, effective agents may be those with non-β-lactam structural motifs.

[0004] The development of synergistic combinations of antibiotics and β-lactamase initiators would also enhance the arsenal of currently available antibiotic treatments.

[0005] The present invention is directed to the development of such new antibacterial therapies and other important goals. Summary of the Invention

[0006] ESKAPE pathogens are becoming increasingly resistant to commonly used β-lactam antibiotics, necessitating the development of antibiotics suitable for treating bacterial infections, such as those with non-β-lactam structural motifs.

[0007] LTV-17 (Formula I; (4S)-2-[(4S)-4-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-3-oxo-1,2-oxazolidin-2-yl]-4-(5,6-dihydroxy-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-5-oxoxolane-2-carboxylic acid) was developed as a lactivicin derivative lacking the β-lactam structural motif (J. Med. Chem. 2014, 57, 3845-3855). [ka]

[0008] Although LTV-17(I) exhibits high antibacterial activity (J. Med. Chem. 2014, 57, 3845-3855), its activity is reduced against many β-lactamase-producing strains, which may contribute to its clinical failure. This is due to the fact that lacticin, although a non-β-lactam antibiotic, is also sensitive to some β-lactamase enzymes.

[0009] However, as detailed below, it has been discovered that combining LTV-17(I) with selected β-lactamase inhibitors has a surprising synergistic effect against susceptible bacteria.

[0010] The present invention is based on this discovery and relates to the following embodiments: (i) drug combinations and medicaments comprising LTV-17 (I) and one or more β-lactamase inhibitors, (ii) the use of such drug combinations and medicaments in the treatment of bacterial infections, and (iii) methods of treating bacterial infections comprising administering LTV-17 (I) together with one or more β-lactamase inhibitors. In each of these embodiments, the β-lactamase inhibitor may be any of a variety of compounds, including, but not limited to, those represented by formula (II). a )~(II z’ Such combinations of LTV-17(I) and β-lactamase inhibitors exhibit synergistic effects when used to treat bacterial infections.

[0011] Specifically, in a first embodiment, the present invention provides the compound LTV-17(I): [ka] or a pharma- ceutically acceptable salt thereof, a solvate thereof, or a solvate of a salt thereof; The present invention relates to a drug combination comprising one or more β-lactamase inhibitors or a pharma- ceutically acceptable salt or a biologically hydrolyzable prodrug thereof.

[0012] In an aspect of this embodiment, the one or more β-lactamase inhibitors include, but are not limited to, compound (II a )~(II z’ ) may be a compound selected from the group consisting of [ka] [ka] [ka]

[0013] These drug combinations of the invention may be used for the treatment and / or prevention of diseases, particularly bacterial infections, in particular gram-negative bacterial infections in human and veterinary medicine, and may also be used as medicaments for the treatment and / or prevention of bacterial infections in human and veterinary medicine.

[0014] In a preferred embodiment of the invention, the drug combination is a synergistic combination, such that the antibacterial activity exhibited by the combination is greater than the sum of the antibacterial activities exhibited individually by (i) LTV-17(I) and (ii) one or more β-lactamase inhibitors present in the combination.

[0015] The pharmaceutical combination of the present invention typically comprises a weight ratio of LTV-17(I) to β-lactamase inhibitor in the range of 20:1 to 1:20. In some embodiments, the ratio is in the range of 1:1 to 1:20.

[0016] The pharmaceutical combinations of the present invention may also include a pharma- ceutically acceptable diluent, excipient or carrier.

[0017] In a second aspect, the present invention relates to a method for treating or preventing bacterial infection in a subject. Such a method comprises administering a therapeutically effective amount of the drug combination of the present invention to a subject in need thereof. Such a subject includes a subject with bacterial infection and a subject at risk of developing bacterial infection.

[0018] Thus, in one aspect of this embodiment, the invention relates to a method of treating or preventing a bacterial infection in a subject, comprising administering to a subject having a bacterial infection a therapeutically effective amount of a drug combination comprising compound LTV-17 (I) or a pharma- ceutically acceptable salt thereof, solvate thereof or solvate of a salt thereof, and one or more β-lactamase inhibitors or pharma- ceutically acceptable salts thereof or biologically hydrolyzable prodrugs thereof.

[0019] In some aspects of such embodiments, the one or more β-lactamase inhibitors include, but are not limited to, compounds (II) as defined herein. a )~(II z’ )

[0020] In some aspects of the embodiment, the bacterial infection is caused by a gram-negative bacteria.

[0021] In some preferred embodiments of the invention, the drug combinations used in the methods of the invention are synergistic combinations, such that the antibacterial activity of the combination is greater than the sum of the antibacterial activities of (i) LTV-17(I) and (ii) one or more β-lactamase inhibitors in the combination separately.

[0022] The drug combinations used in the methods of the present invention typically have a weight ratio of LTV-17(I) to β-lactamase inhibitor ranging from 20:1 to 1:20. In some embodiments, the ratio ranges from 1:1 to 1:20.

[0023] The drug combinations used in the methods of the present invention may include a pharma- ceutically acceptable diluent, excipient or carrier.

[0024] The subject to treatment can be any subject for which the pharmaceutical combination of the present invention has a therapeutic effect, for example a human. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0025] Detailed description of the invention: The lacticin class of antibacterial agents is active against a range of Gram-positive and Gram-negative bacteria. These compounds have a unique bicyclic peptide core that exhibits superior antibacterial activity, especially against Gram(-) microorganisms. Natural lacticin is a non-β-lactam antibiotic, 2-[(4S)-4-acetamido-3-oxo-1,2-oxazolidin-2-yl]-5-oxoxolane-2-carboxylic acid, which, when modified with an acylamino moiety at the C-4 position and replaced with a 2-aminothiazol-4-yl-(Z)-2-methoxy-iminoacetyl side chain, showed improved antibacterial activity.

[0026] LTV-17 (Formula I; (4S)-2-[(4S)-4-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-3-oxo-1,2-oxazolidin-2-yl]-4-(5,6-dihydroxy-1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-5-oxoxolane-2-carboxylic acid) is a activicicin derivative with a catechol moiety in the molecule, which utilizes a broad Ton-B-dependent iron transport mechanism and thus enhances siderophore receptor-mediated uptake through the bacterial outer membrane. The present invention relates to the combination of LTV-17(I) with various β-lactamase inhibitors that show synergistic activity against many antibiotic-resistant bacteria.

[0027] Pharmaceutical Combinations As summarized above, the present invention relates to a drug combination comprising the compound LTV-17 (I) or a pharma- ceutically acceptable salt thereof, a solvate thereof, or a solvate of a salt thereof, and one or more β-lactamase inhibitors or a pharma- ceutically acceptable salt thereof or a biologically hydrolyzable prodrug thereof. In an embodiment of the present invention, the one or more β-lactamase inhibitors include, but are not limited to, the compounds described herein (II a )~(II z’)

[0028] These drug combinations of the present invention can be used for the treatment and / or prevention of diseases in human and veterinary medicine, particularly bacterial infections, in particular gram-negative bacterial infections.They can also be used as medicines for the treatment and / or prevention of bacterial infections in human and veterinary medicine.

[0029] method As further summarized above, the present invention also relates to a method for treating or preventing bacterial infection in a subject. Such a method comprises administering a therapeutically effective amount of the drug combination of the present invention to a subject in need thereof. Such subjects include those who have bacterial infection and those at risk of developing bacterial infection.

[0030] As a non-limiting example, the present invention relates to a method of treating or preventing a bacterial infection in a subject, comprising administering a therapeutically effective amount of a drug combination comprising the compound LTV-17 (I) or a pharma- ceutically acceptable salt thereof, a solvate thereof, or a solvate of a salt thereof. In an embodiment of the present invention, the one or more β-lactamase inhibitors are selected from the group consisting of the compounds described herein (II). a )~(II z’ ), but is not limited to these.

[0031] As used in the embodiments and aspects of the present invention, the term "β-lactamase inhibitor" refers to a compound capable of inhibiting β-lactamase activity, where inhibitory activity means inhibiting the activity of class A, B, C and / or D β-lactamases by at least 50%, 60%, 70%, 80%, 90%, or 95% or more. Suitable β-lactamase inhibitors for use in the combinations and methods of the present invention include the compounds described herein (II a )~(II z’ ) are included.

[0032] As used in various embodiments and aspects of the present invention, the term "β-lactamase" refers to an enzyme capable of inactivating β-lactam antibiotics.

[0033] The present invention further relates to a method for the preparation of a medicament which may be used in the treatment and / or prophylaxis of a disease, in particular a bacterial infection, comprising administering to said patient a compound according to the present invention, i.e. LTV-17 (I) and one or more β-lactamase inhibitors, such as compounds of the formula (II a )~(II z’ or a pharma- ceutically acceptable salt or biologically hydrolyzable prodrug thereof.

[0034] The present invention further relates to a compound represented by the above formula (II) in combination with LTV-17 (I) or a pharma- ceutical acceptable carrier or diluent. a )~(II z’ or a pharma- ceutical comprising one or more β-lactamase inhibitors selected from any one of the following:

[0035] The Drug Combinations of the present invention are particularly useful in human and veterinary medicine for the prevention and treatment of local and systemic infections.

[0036] A "drug combination" according to the present invention means a physical combination of LTV-17(I) with one or more β-lactamase inhibitors as described above in appropriate ratios.

[0037] Specifically, in a drug composition or medicament containing a "drug combination" of LTV-17(I) and one or more β-lactamase inhibitors, the weight ratio of active ingredient to carrier is usually in the range of 1:20 to 20: 1. In some embodiments, the ratio is in the range of 1:1 to 1:20.

[0038] Among the "pharmaceutical combinations" of the present invention are those which, in one combination, include salts, solvates and solvates of the salts of LTV-17(I).

[0039] The "drug combinations" of the present invention may include compounds that contain enantiomers or diastereomers, and their respective mixtures.

[0040] The "drug combinations" of the present invention may include compounds that contain tautomers, and thus the present invention encompasses all tautomers.

[0041] When co-administered with a β-lactamase inhibitor, LTV-17(I) produces a synergistic effect. The term "synergistic effect" refers to an effect that occurs when two or more drugs are administered together that is greater than the effect that occurs when those drugs are administered individually.

[0042] While LTV-17(I) and one or more β-lactamase inhibitors may be administered simultaneously to a subject, either in a sample pharmaceutical formulation or in separate pharmaceutical formulations, thus forming the basis of the "drug combination" of the present invention, it should be understood that LTV-17(I) or a pharmaceutically acceptable salt thereof may be administered as separate agents in a course of treatment in which a β-lactamase inhibitor or a pharmaceutically acceptable salt thereof or a biologically hydrolyzable prodrug thereof is also administered separately. Thus, LTV-17(I) and one or more β-lactamase inhibitors may be administered sequentially or simultaneously, in any order, with overlapping or non-overlapping administration periods. Even when these agents are administered sequentially, with no overlapping administration periods, synergistic effects can be obtained if they are administered close in time, for example, if the two agents are administered within one hour of each other.

[0043] A "therapeutically effective amount" refers to the amount of a drug combination that, when administered to a subject for treating a disease, is sufficient to affect such treatment of the disease, disorder or condition. The therapeutically effective amount can vary depending on, for example, the "drug combination," the disease, disorder, symptoms of the disease, the severity of the disease or disorder, and / or the age, weight, and / or health of the patient being treated.

[0044] Typically, the therapeutically effective amount of the drug combination of the present invention for an adult is about 50 mg to about 3000 mg of active agents. In other embodiments, the therapeutically effective amount is about 100 mg to about 2000 mg. In other embodiments, the therapeutically effective amount is about 500 mg to about 1200 mg. Typically, dosages (as stated) are given 1 to 4 times per day. In one embodiment, dosages are given 3 times per day. In some cases, it may be necessary to give dosages outside these ranges.

[0045] The terms "dose," "unit dose," "unit administration," or "effective dose" refer to a physically discrete unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect.

[0046] The present invention further relates to medicaments comprising the drug combinations of the present invention, usually together with one or more inert, non-toxic, pharma- ceutically acceptable carriers or diluents, and their use for the above-mentioned purposes.The compositions can be in the form of injections, suspensions, emulsions, coated tablets, pellets, gelatin capsules, capsules containing liquids, powders, granules, sustained release formulations, suppositories, aerosols, sprays, ointments, creams, or any other form suitable for use.

[0047] The "drug combinations" may act systemically or locally. They may be administered for this purpose, for example, parenterally, pulmonary, nasally, sublingually, lingually, buccally, rectally, dermally, transdermally, conjunctivally, auricleally, or in any manner suitable therefor, or as an implant or stent.

[0048] For these administration routes, the "drug combination" of the present invention can be administered in an appropriate dosage form. Thus, the drug combination of the present invention may include a pharma- ceutically acceptable diluent, excipient, or carrier.

[0049] Parenteral administration can be carried out by avoiding the absorption process (e.g., intravenous, intraarterial, intracardiac, intravertebral or intralumbar) or by including the absorption process (e.g., intramuscular, subcutaneous, intradermal, transdermal or intraperitoneal). Suitable dosage forms for parenteral administration are, in particular, injection and infusion preparations in the form of solutions, suspensions, emulsions, lyophilisates or sterile powders.

[0050] Suitable for other administration routes are, for example, pharmaceutical forms for inhalation (in particular powder inhalers, nebulizers), nasal drops, solutions, sprays, tablets, films / wafers or capsules, for lingual, sublingual or buccal administration, suppositories, ear or eye preparations, aqueous suspensions (lotions, shaking mixtures), lipophilic suspensions, ointments, creams, transdermal therapeutic systems (patches etc.), pastes, foams, dusting powders, implants or stents.

[0051] The drug combination of the present invention can be converted into the described administration form, i.e. the drug composition of the present invention. This can be done in a manner known per se, by adding an inert, non-toxic pharma- ceutically acceptable carrier or diluent, such as starch, glucose, lactose, sucrose, gelatin, gum arabic, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene glycol, water, water for injection, physiological saline, buffered saline, dextrose, glycerol, ethanol, propylene glycol, polysorbate 80 (Tween-80), ... TM), poly(ethylene) glycol 300 and 400 (PEG 300 and 400), PEGylated castor oil (e.g., Cremophor EL), poloxamer 407 and 188, hydrophilic and hydrophobic carriers, and combinations thereof. Hydrophobic carriers include, for example, lipid emulsions, lipids, PEGylated phospholipids, polymer matrices, biocompatible polymers, lipospheres, vesicles, particles, and liposomes. These terms specifically exclude cell culture media.

[0052] If desired, the pharmaceutical composition of the present invention can also contain a small amount of wetting agent (e.g., sodium dodecyl sulfate, polyoxyethylene sorbitan oleate), dispersing or emulsifying agent, or pH buffering agent, and preservative. In addition, auxiliary agents, stabilizers, thickeners, lubricants, and coloring agents can be included. The pharmaceutical composition can be formulated in a conventional manner. The appropriate formulation depends on the selected route of administration.

[0053] In pharmaceutical compositions containing the pharmaceutical combination of the present invention, the weight ratio of active ingredient to carrier will usually range from 1:20 to 20:1.

[0054] Examples of bacteria against which the compounds of the present invention have antibacterial activity include bacteria from the order Enterobacterales, Escherichia coli, Enterobacter spp., Klebsiella spp., Serratia spp., Pseudomonas spp., Stenotrophomonas spp., Citrobacter spp., Acinetobacter spp., Campylobacter spp., Helicobacter spp., Vibrio spp., Bordetella spp., and the like. spp., Salmonella spp., Shigella spp., Francisella spp., Burkholderia spp., Clostridia spp., Alcaligenes spp., Moraxella spp., Proteus spp., Neisseria spp., Haemophilus spp., Achromobacter spp., and Erwinia spp., but are not limited to these. Particular genera of bacteria against which the compounds of the present invention have antibacterial activity include, but are not limited to, one or more of the ESKAPE pathogens, namely, Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species.

[0055] Veterinary animals that may be treated using the drug combinations and methods of the present invention include, but are not limited to, non-human primates, birds, horses, cows, goats, sheep, dogs, cats, or companion animals such as rodents, or other mammals.

[0056] Examples The synergistic activity of drug combinations is shown in Table 1, without being limited to specific combinations. Table 1: β-lactamase inhibitors (II j Synergistic activity of LTV-17(I) in combination with avibactam (II j MIC (μg / ml) of LTV-17(I) with and without [Table 1]

[0057] In vitro antibacterial evaluation method Isolates: Representative resistant strains of class-C β-lactamase-producing bacteria, including Escherichia coli, Citrobacter freundii, Enterobacter cloacae, Klebsiella pneumoniae, and Proteus mirabilis, were used to treat LTV-17(I) with β-lactamase inhibitors (II). j The synergistic effect of adding

[0058] Minimum inhibitory concentration (MIC) test method: All antibiotics were tested by both the broth microdilution method according to the Clinical and Laboratory Standards Institute (CLSI) recommendation (M07) and the modified CLSI method including the iron-deficient CA-MHB protocol. MIC was defined as the lowest concentration of antibiotic to obtain clear wells in a 96-well plate. MIC interpretation was based on the breakpoint criteria of CLSI M100-23S (2013) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST; 2013). Synergy was evaluated based on the number of two-fold dilution reductions of MIC against the same strains for LTV-17 (I) and the β-lactamase inhibitor avibactam (II). j The synergistic effect was calculated by comparing the combination of LTV-17(I) with the combination of LTV-17(I) with the combination of LTV-17(I). The greater the number of two-fold reductions, the stronger the synergistic effect.

[0059] Test results LTV-17 (I) and avibactam (II j ) demonstrated synergy against the test strains, with two-fold reductions in MICs ranging from 2-fold to more than 9-fold. Avibactam was tested at a fixed concentration of 4 μg / mL. The results suggest that the addition of a β-lactamase inhibitor to LTV-17(I) significantly impacts the reduction in the concentration of LTV-17(I) required to inhibit bacterial growth. This also suggests that the combination could be used as a therapeutic prophylaxis or for the treatment of infections due to resistant strains of Gram-negative bacteria.

Claims

1. Compound LTV-17(I): 【Chemistry 1】 or a pharma- ceutically acceptable salt thereof, a solvate thereof, or a solvate of a salt thereof; A drug combination comprising one or more β-lactamase inhibitors or a pharma- ceutically acceptable salt or a biologically hydrolyzable prodrug thereof.

2. The one or more β-lactamase inhibitors are selected from the group consisting of compound (II a ) ~ (II z’ ): 【Chemistry 2-1】 【Chemistry 2-2】 【Chemistry 2-3】 2. The drug combination of claim 1, selected from the group consisting of:

3. 3. A drug combination according to claim 1 or 2 for use in the treatment and / or prevention of a disease, in particular a bacterial infection, in particular a gram-negative bacterial infection.

4. 4. A drug combination according to any one of claims 1 to 3 which is a synergistic combination.

5. 5. The drug combination of any one of claims 1 to 4, wherein the weight ratio of LTV-17(I) to the β-lactamase inhibitor in said combination ranges from 20:1 to 1:

20.

6. 6. The drug combination of claim 5, wherein the ratio ranges from 1:1 to 1:

20.

7. 3. A pharmaceutical combination as claimed in claim 1 or 2 for use as a medicament for the treatment and / or prevention of bacterial infections in human and veterinary medicine.

8. The pharmaceutical combination of any one of claims 1 to 7, further comprising a pharma- ceutically acceptable diluent, excipient or carrier.

9. 1. A method of treating or preventing a bacterial infection in a subject, comprising: Compound LTV-17(I): 【Chemistry 3】 or a pharmaceutically acceptable salt thereof, solvate thereof, or a solvate of a salt thereof, and one or more β-lactamase inhibitors or a pharmaceutically acceptable salt thereof, or a biologically hydrolyzable prodrug thereof, to a subject having a bacterial infection.

10. The one or more β-lactamase inhibitors are selected from the group consisting of compound (II a ) ~ (II z’ ): 【Chemistry 4-1】 【Chemistry 4-2】 【Chemistry 4-3】 【Chemistry 4-4】 10. The method of claim 9, selected from the group consisting of:

11. 11. The method of claim 9 or 10, wherein the bacterial infection is caused by a gram-negative bacteria.

12. The method of any one of claims 9 to 11, wherein the subject is a human.

13. The method of any one of claims 9 to 12, wherein the weight ratio of LTV-17(I) to the beta-lactamase inhibitor in said combination ranges from 20:1 to 1:

20.

14. 14. The method of claim 13, wherein the ratio ranges from 1:1 to 1:

20.

15. The method of any one of claims 9 to 14, wherein the combination has a synergistic antibacterial effect.

16. The method of any one of claims 9 to 15, wherein the drug combination further comprises a pharma- ceutically acceptable diluent, excipient, or carrier.

Citation Information

Patent Citations

  • Lactivicin compounds, their preparation and use as antibacterial agents

    JP7551186B2